Authors:
Slamon, DJ
Leyland-Jones, B
Shak, S
Fuchs, H
Paton, V
Bajamonde, A
Fleming, T
Eiermann, W
Wolter, J
Pegram, M
Baselga, J
Norton, L
Citation: Dj. Slamon et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastaticbreast cancer that overexpresses HER2., N ENG J MED, 344(11), 2001, pp. 783-792
Authors:
Elhilali, MM
Gleave, M
Fradet, Y
Davis, I
Venner, P
Saad, F
Klotz, L
Moore, R
Ernst, S
Paton, V
Citation: Mm. Elhilali et al., Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma, BJU INT, 86(6), 2000, pp. 613-618
Citation: Jd. Brooks et V. Paton, Potent induction of carcinogen defence enzymes with sulforaphane, a putative prostate cancer chemopreventive agent, PROSTATE C, 2, 1999, pp. S8-S8
Authors:
Cobleigh, MA
Vogel, CL
Tripathy, D
Robert, NJ
Scholl, S
Fehrenbacher, L
Wolter, JM
Paton, V
Shak, S
Lieberman, G
Slamon, DJ
Citation: Ma. Cobleigh et al., Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease, J CL ONCOL, 17(9), 1999, pp. 2639-2648